Adoption of Lutetium-(177) PSMA radioligand therapy for metastatic castration resistant prostate cancer: a total population analysis in Germany from 2016 to 2020

PURPOSE: This study is to investigate the adoption and current trends of Lutetium-(177) PSMA RLT for mCRPC in Germany. METHODS: We analyzed data from the reimbursement.INFO tool based on German hospitals’ quality reports for Lutetium-(177) PSMA RLT from 2016 to 2020 and from the nationwide German ho...

Descripción completa

Detalles Bibliográficos
Autores principales: Flegar, Luka, Thoduka, Smita George, Librizzi, Damiano, Luster, Markus, Zacharis, Aristeidis, Heers, Hendrik, Eisenmenger, Nicole, Ahmadzadehfar, Hojjat, Eiber, Matthias, Weber, Wolfgang, Groeben, Christer, Huber, Johannes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10199877/
https://www.ncbi.nlm.nih.gov/pubmed/36826478
http://dx.doi.org/10.1007/s00259-023-06139-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10199877/
https://www.ncbi.nlm.nih.gov/pubmed/36826478
http://dx.doi.org/10.1007/s00259-023-06139-x

Ejemplares similares